These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia. Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M Front Immunol; 2021; 12():766272. PubMed ID: 34912339 [TBL] [Abstract][Full Text] [Related]
24. Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia. Fischer K; Al-Sawaf O; Hallek M Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):357-362. PubMed ID: 33275717 [TBL] [Abstract][Full Text] [Related]
25. Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia. Egyed M; Lueff S; Borbely J; Illes A Future Oncol; 2022 Mar; 18(7):755-769. PubMed ID: 35139644 [TBL] [Abstract][Full Text] [Related]
26. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma. Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061 [TBL] [Abstract][Full Text] [Related]
27. Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review. Shadman M JAMA; 2023 Mar; 329(11):918-932. PubMed ID: 36943212 [TBL] [Abstract][Full Text] [Related]
28. Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations. Cramer P; Tausch E; von Tresckow J; Giza A; Robrecht S; Schneider C; Fürstenau M; Langerbeins P; Al-Sawaf O; Pelzer BW; Fink AM; Fischer K; Wendtner CM; Eichhorst B; Kneba M; Stilgenbauer S; Hallek M Blood; 2021 Nov; 138(19):1805-1816. PubMed ID: 34086865 [TBL] [Abstract][Full Text] [Related]
37. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. Davids MS; Lampson BL; Tyekucheva S; Wang Z; Lowney JC; Pazienza S; Montegaard J; Patterson V; Weinstock M; Crombie JL; Ng SY; Kim AI; Jacobson CA; LaCasce AS; Armand P; Arnason JE; Fisher DC; Brown JR Lancet Oncol; 2021 Oct; 22(10):1391-1402. PubMed ID: 34534514 [TBL] [Abstract][Full Text] [Related]
38. Severe infections in patients with chronic lymphocytic leukemia included in trials investigating BTK and BCL2 inhibitors. Mauro FR; Frustaci AM; Visentin A; Vitale C; Bartoletti M; Oltolini C; Zappulo E; Mikulska M Crit Rev Oncol Hematol; 2024 Sep; 201():104408. PubMed ID: 38880368 [TBL] [Abstract][Full Text] [Related]
39. Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm. Scheffold A; Stilgenbauer S Curr Oncol Rep; 2020 Feb; 22(2):16. PubMed ID: 32025827 [TBL] [Abstract][Full Text] [Related]
40. The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia. Vitale C; Ferrajoli A Expert Rev Hematol; 2020 Aug; 13(8):885-894. PubMed ID: 32700593 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]